TG Therapeutics Unveils Data Presentation Schedule for BRIUMVI®

Author: Evelyn Baker Updated: 09-10-2025 07:45 AM

Upcoming Data Presentations for BRIUMVI®

TG Therapeutics, Inc. (NASDAQ: TGTX), proudly announces an exciting schedule showcasing BRIUMVI® (ublituximab-xiiy) data for relapsing forms of multiple sclerosis (RMS). This information will be presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting taking place in Barcelona.

Presentation Highlights

The event will span three days, from September 24 to 26. Renowned experts will share findings pertaining to the efficacy and safety of BRIUMVI® in managing RMS.

Key Presentations Scheduled

Oral Presentation Details

One of the key presentations titled "Long-term Efficacy and Safety of Ublituximab in Relapsing Multiple Sclerosis: Results from Six Years of ULTIMATE I and II Open-label Extension" is set for September 24. It will occur at 14:55 CEST, offering insights into six years of research data.

Session: Therapeutic Interventions - Lecture Hall 117
Abstract Number: ECTRIMS25-1571
Lead Author: Dr. Bruce Cree from the Weill Institute for Neurosciences, University of California

ePoster Presentations

Attendees can also look forward to several ePoster presentations, covering topics such as:

Updates from the ENHANCE Study: This presentation focuses on the safety and tolerability of a modified ublituximab dosing regimen. It details the results from extensive clinical assessments.
Real-World Experience from the ENABLE Study: Another ePoster highlights the clinical experience of patients commencing treatment with BRIUMVI®, showcasing real-world outcomes from a Phase 4 observational study.

About BRIUMVI® (ublituximab-xiiy)

BRIUMVI® represents an innovative approach in treating various autoimmune disorders, specifically targeting CD20-expressing B-cells. This monoclonal antibody's unique construction enhances its effectiveness in B-cell depletion, providing significant promise for RMS patients.

Current Indications

In the United States and Europe, BRIUMVI® holds approval for treating adult patients exhibiting active RMS. Its operational advantages lead to impressive clinical outcomes that resonate with healthcare professionals and patients alike.

Further Steps and Availability of Data

Post-presentation, comprehensive data will be accessible through the Publications page on TG Therapeutics' official website. This ensures ongoing transparency and information dissemination regarding BRIUMVI®.

Frequently Asked Questions

What is the focus of TG Therapeutics's upcoming presentations?

The presentations will highlight the efficacy and safety of BRIUMVI® in treating relapsing multiple sclerosis at the ECTRIMS annual meeting.

When is the presentation scheduled?

The main oral presentation will take place on September 24 at 14:55 CEST.

Where can I find the data post-presentation?

The data discussed will be available on the Publications page of TG Therapeutics’ website.

Who leads the oral presentation?

Dr. Bruce Cree, from the Weill Institute for Neurosciences, will lead the oral presentation.

What is BRIUMVI® used for?

BRIUMVI® is indicated for treating adult patients with active relapsing multiple sclerosis.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.